- Home
- OPFI vs LUNG Comparison
OPFI vs LUNG Comparison
Compare OPFI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPFI | LUNG |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 63.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPFI | LUNG |
|---|---|---|
| Price | $10.81 | $2.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $13.50 | $6.81 |
| AVG Volume (30 Days) | 519.3K | ★ 1.0M |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $335,423,000.00 | $91,664,000.00 |
| Revenue This Year | $120.32 | $9.21 |
| Revenue Next Year | $10.85 | $5.03 |
| P/E Ratio | $79.89 | ★ N/A |
| Revenue Growth | ★ 28.69 | 15.59 |
| 52 Week Low | $6.81 | $1.31 |
| 52 Week High | $17.73 | $9.37 |
Technical Indicators
Market Signals| Indicator | OPFI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 69.24 |
| Support Level | $10.56 | $2.43 |
| Resistance Level | $11.35 | $2.66 |
| Average True Range (ATR) | 0.39 | 0.20 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 66.67 | 89.22 |
Price Performance
Historical ComparisonAbout OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.